Brain research with organoids

Scientists develop effective method to genetically modify brain organoids

23-May-2023 - Primates are among the most intelligent creatures with distinct cognitive abilities. Their brains are relatively large in relation to their body stature and have a complex structure. However, how the brain has developed over the course of evolution and which genes are responsible for the high ...

Using mRNA delivery to improve muscle strength

Targeted correction of genetic defects

16-Mar-2022 - Mutations that lead to muscle atrophy can be repaired with the gene editor CRISPR-Cas9. A team led by ECRC researcher Helena Escobar has now introduced the tool into human muscle stem cells for the first time using mRNA, thus discovering a method suitable for therapeutic applications. It may be ...

Electric shocks used to kill bacteria

Electric fields destroy Listeria without damaging nutrients

25-Oct-2018 - Low temperatures and an acidic environment create the ideal conditions for applying an effective method of inactivating Listeria (and other germs) in the processing of whey protein solutions – without destroying valuable nutrients. A team from the University of Natural Resources and Life ...

Quantum dots illuminate transport within the cell

23-Mar-2017 - The quantum dots used by the researchers are particles of semi-conducting material just a few nanometres wide, and are the subject of great interest because of their potential for use in photovoltaic cells or computers. "The great thing about these particles is that they absorb light and emit it ...

Cellectis acquires assets from Cyto Pulse Sciences Inc.

13-Sep-2010 - Cellectis has announced that it has acquired all the assets of Cyto Pulse Sciences Inc., a US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment. The transaction value of $2.2 million was paid in cash and closed on ...

Cell Projects licenses Electroporation Technologies from Queen’s University, Canada

16-Oct-2008 - Cell Projects (UK) has entered into a wide ranging commercial license and joint development agreement with Queen’s University, Kingston, Ontario, Canada, covering several new Electroporation platform technologies for Adherent and InSitu Cell Electroporation. The ground-breaking technology allows ...

Pharmexa and Ichor Medical Systems enter into an agreement to co-develop multiple DNA vaccines delivered by electroporation

12-Mar-2008 - Pharmexa and Ichor have entered into an agreement to co-develop multiple DNA vaccines to combat important diseases of high unmet medical need. It is well recognized that in vivo electroporation is a promising means of enhancing the potency of DNA vaccines. The co-development programmes include a ...

Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C

Inovio initiates 5th DNA vaccine clinical study: hepatitis C

01-Nov-2007 - Inovio Biomedical Corporation announced that its partner, Tripep AB of Sweden, has begun enrolling patients for its Phase I/II clinical study of a novel DNA vaccine designed to treat chronically infected hepatitis C virus (HCV) patients. The trial will test Tripep's proprietary DNA vaccine, ...

Inovio Biomedical Redirects Strategic Emphasis toward DNA Vaccines and DNA Delivery

Company expanding R&D to advance its DNA delivery technology and develop proprietary DNA vaccines for cancer and chronic infectious diseases

11-Oct-2007 - Inovio Biomedical Corporation announced it is focusing its research and development efforts on its electroporation-mediated DNA delivery technology and DNA vaccines with the objective of further building potential downstream value to existing and prospective partners. Overall, management has ...

Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine

Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using Inovio's Electroporation DNA Delivery Technology

25-May-2007 - Inovio Biomedical Corp., focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced that interim data from a clinical study of an experimental DNA-based prostate cancer vaccine demonstrated that ...